News
01-26-2016, 10:13 PM
Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.
More... (http://www.news-medical.net/news/20160127/Results-from-STRIVE-trial-of-enzalutamide-versus-bicalutamide-in-CRPC-published-in-Journal-of-Clinical-Oncology.aspx)
More... (http://www.news-medical.net/news/20160127/Results-from-STRIVE-trial-of-enzalutamide-versus-bicalutamide-in-CRPC-published-in-Journal-of-Clinical-Oncology.aspx)